PFIZER INC Q4 FY2024 earnings call

• Seagen Integration: Successfully integrated Seagen, creating a leading oncology company.
• Commercial Restructuring: Split commercial ops into US and international divisions, consolidated agencies, AI-driven marketing, achieved top rankings in field force.
• R&D Pipeline: Over a dozen approvals, seven pivotal study starts, eight key Phase 3 readouts; new R&D structure with four end-to-end units for oncology, vaccines, internal medicine, inflammation/immunology.
• Financial Discipline: Ended 2024 with expanded margins, de-levered $7.8B, returned $9.5B to shareholders.
• 2025 Priorities: Focus on R&D productivity, margin expansion, commercial excellence, capital allocation.

Oncology: Integrated Seagen, with products like Padcev (top first-line treatment for urothelial cancer), BRAFTOVI/Mektovi (27% YOY growth in BRAF tumors), Lorbrena (37% YOY growth in ALK-positive NSCLC), ELREXFIO ($130M+ revenue in triple-refractory multiple myeloma). COVID-19 Portfolio: Stabilizing patterns, multi-year contracts in international markets. Vyndaqel Family: 90% YOY growth in US, 32% operational growth internationally. Eliquis: 10% worldwide YOY operational growth. Nurtec: 36% worldwide YOY operational growth, 49% market share in oral CGRP for migraine. Respiratory Vaccines (Abrysvo, Prevnar 20): Abrysvo had ~13% market share increase in shipped doses, Prevnar 20 saw volume decrease in US adult RSV but positive momentum in Europe, Latin America, and maternal indication.

• Full-year 2025 revenue expected $61B-$64B, adjusted diluted EPS $2.80-$3.00.
• Aim to achieve $4.5B net savings from cost realignment by end of 2025.
• IRA Medicare Part D redesign to be ~$1B headwind to revenue.
• Committed to de-levering to 3.25x gross leverage by end of 2025.

• Regulatory/Policy: Potential impact of new HHS leadership on vaccines and regulations.
• Market Competition: Abrysvo faced market volume decrease in US adult RSV; competition in sectors like Vyndaqel.
• Pipeline Uncertainty: Outcomes of drug development studies, e.g., danuglipron dose optimization data.

Q: On danuglipron dose optimization data, range of possible outcomes and next steps?

A: Chris Boshoff stated on track for Q1 data, which will determine the future of danuglipron.

Q: RFK Jr. as HHS Secretary, impact on vaccines?

A: Albert Bourla was cautiously optimistic, focusing on collaboration in chronic diseases and cancer despite potential vaccine-related concerns.

Q: Prevnar 25-valent Phase 3 start and pediatric data?

A: Chris Boshoff said PCV-25 Phase 2 ongoing, showing best-in-class immunogenicity against serotype 3, with pediatric study ongoing.

Q: Ponsegromab in heart failure?

A: Chris Boshoff said stopped cardiovascular study, cancer cachexia Phase 3 study starting later in 2025.